Page last updated: 2024-08-23

paroxetine and aprepitant

paroxetine has been researched along with aprepitant in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (22.22)	18.2507
2000's	2 (22.22)	29.6817
2010's	5 (55.56)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Carlson, EJ; Carman, J; Cascieri, MA; Chicchi, GG; Cutler, N; Feighner, J; Hale, JJ; Hargreaves, RJ; Harrison, T; Hefti, F; Hewson, L; Hill, RG; Kramer, MS; Liu, G; MacCoss, M; Mills, SG; Reines, SA; Rupniak, NM; Sadowski, S; Scolnick, EM; Shrivastava, R; Smith, D; Snavely, D; Sramek, JJ; Swain, CJ; Williams, AR; Wyatt-Knowles, E	1
Nutt, D	1
Krishnan, R; Ranga, K	1
Brocco, M; Cremers, TI; de Jong, TR; de Nanteuil, G; Dekeyne, A; Di Cara, B; Flik, G; Gobert, A; Lejeune, F; Mannoury la Cour, C; Millan, MJ; Olivier, B; Rivet, JM	1
Ball, WA; Hargreaves, RJ; Lines, C; Reines, SA; Snavely, DB; Szegedi, A	1
Ball, W; Cai, B; DeMuro, C; Morrison, MF; Snyder, E	1

Reviews

1 review(s) available for paroxetine and aprepitant

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

5 trial(s) available for paroxetine and aprepitant

Article	Year
Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (New York, N.Y.), 1998, Sep-11, Volume: 281, Issue:5383 Topics: Adolescent; Adult; Aged; Amygdala; Animals; Antidepressive Agents, Second-Generation; Aprepitant; Behavior, Animal; Brain; Depressive Disorder; Female; Gerbillinae; Guinea Pigs; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Norepinephrine; Paroxetine; Receptors, Neurokinin-1; Serotonin; Stress, Psychological; Substance P; Vocalization, Animal	1998
Substance-P antagonists: a new treatment for depression? Lancet (London, England), 1998, Nov-21, Volume: 352, Issue:9141 Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance P	1998
Clinical experience with substance P receptor (NK1) antagonists in depression. The Journal of clinical psychiatry, 2002, Volume: 63 Suppl 11 Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome	2002
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Human psychopharmacology, 2014, Volume: 29, Issue:6 Topics: Adult; Antidepressive Agents; Aprepitant; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2014
A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018, 11-15, Volume: 14, Issue:11 Topics: Adult; Aged; Aprepitant; Comorbidity; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine; Psychometrics; Reproducibility of Results; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires	2018

Other Studies

3 other study(ies) available for paroxetine and aprepitant

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Species independence in brain tissue binding using brain homogenates. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7 Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity	2011
S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:9 Topics: Animals; Antidepressive Agents; Aprepitant; Behavior, Animal; Brain; Extracellular Signal-Regulated MAP Kinases; Female; Gerbillinae; Guinea Pigs; Humans; Indans; Male; Mice; Morpholines; Motor Activity; Neurokinin-1 Receptor Antagonists; Pain Measurement; Paroxetine; Piperazines; Pregnancy; Radioligand Assay; Rats; Rats, Wistar; Receptors, Neurokinin-1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stress, Physiological	2010